FLOW was the only trial listed with a primary kidney outcome, specifically designed to assess the effect of a GLP-1 receptor agonist on major kidney events
Semaglutide So, to share the difference between the 2 peptides, Im going to quote some official sources vs
1 Background: metabolic-reproductive challenges of PCOS across lifespan 1.1 Epidemiology and reproductive impact Polycystic Ovary Syndrome (PCOS) is recognized not only as a reproductive disorder in women of childbearing age but also as a complex, lifelong cardiometabolic risk state (6)
Common side effects include nausea, vomiting, diarrhea, constipation, and stomach discomfort, particularly at the start of treatment
In rare cases, alcohol use while on GLP-1s may increase the risk of pancreatitis
So theres at least some possible risk here